北京生命科学研究所研究员，生物制品中心主任JianhuaSui,Ph.D.AssistantInvestigatorandDirectorofBiologicsResearchCenter,NIBS,Beijing，ChinaPhone：86-10-80726688-8630
Fax：86-10-80726021E-mail：suijianhua@nibs.ac.cn
研究概述北京生命科学研究所生物制品中心成立于2012年。中心以重要感染性疾病，自身免疫疾病及肿瘤为研究对象，将基础生物学研究与医学应用相结合，开展以人抗体为主体的相关研究。主要包括：1）发现和确认新型治疗性靶分子;2）开发治疗性人源抗体;3）发展新型抗体工程技术;4）以抗体为主的生物大分子制备和抗体新药临床前研究及评估等。ResearchDescriptionTheBiologicsCenteratNIBSisaresearch-orientedcenterestablishedin2012.Weconducthumanantibodyrelatedresearchesattheintersectionofbiologyandmedicine;wetakeinterdisciplinaryapproachestodevelopinnovativebiologicsfordiseasespreventionandtherapy.Thecentermainlyfocusesoninfectiousdiseases,autoimmunediseasesandcancer.Researchprogramsinclude:1)identificationandvalidationofnoveltherapeutictargets;2)developmentoftherapeutichumanmonoclonalantibodies;3)developnewantibodyengineeringtechnologies;4)biologicsproductionandpre-clinicalvalidationofnewantibodydrugs,etc.教育经历：Education2000中国协和医科大学中国医学科学院血液学研究所病理生理学博士Ph.D.Pathophysiology,InstituteofHematology,PekingUnionMedicalCollege&ChineseAcademyofMedicalSciences,China1997兰州大学医学院心血管内科学硕士M.S.Cardiovascology,LanzhouMedicalSchool,LanzhouUniversity,China1994兰州大学医学院临床医学学士B.S.ClinicalMedicine,LanzhouMedicalSchool,LanzhouUniversity,China工作经历ProfessionalExperience2012–北京生命科学研究所研究员，生物制品中心主任AssistantInvestigatorandDirectorofBiologicsResearchCenterNationalInstituteofBiologicalSciences,Beijing,China2004–2011哈佛大学医学院Dana-Farber癌症研究所讲师InstructorDepartmentofCancerImmunology&AIDS,Dana-FarberCancerInstitute,DepartmentofMedicine,HarvardMedicalSchool,Boston,US2000–2004哈佛大学医学院Dana-Farber癌症研究所博士后PostdoctoralFellowDepartmentofCancerImmunology&AIDS,Dana-FarberCancerInstitute,DepartmentofMedicine,HarvardMedicalSchool,Boston,US奖励和资助AwardsandHonors2012–青年千人“ThousandYoungTalents”,China2007–2008哈佛大学医学院优秀妇女健康研究基金HarvardMedicalSchool(HMS)FundforExcellentWomen’sHealthResearch2003–2006TheSusanG.Komen乳腺癌基金会博士后基金TheSusanG.KomenBreastCancerFoundationPostdoctoralFellowship部分发表文章SelectedPublications1.SuiJ,SheehanJ,HwangWC,BankstonLA,BurchettSK,HuangCY,LiddingtonRC,BeigelJH,MarascoWA.WidePrevalenceofHeterosubtypicBroadlyNeutralizingHumanAnti-InfluenzaAAntibodies.ClinInfectDis2011;52(8):1003-1009CommentinClinInfectDis:DonisR,andCoxN.ProspectingtheInfluenzaHemagglutinintoDevelopUniversalVaccines,ClinInfectDis(Editorialcommentary)2011,52:1010-1012.2.SuiJ*(*co-correspondingauthor),HwangWC,PerezS,WeiG,AirdD,ChenL,SantelliE,StecB,CadwellG,AliM,MurakamiA,YammanuruA,HanT,CoxN,BankstonLA,DonisRO,LiddingtonRCandMarascoWA.StructuralandFunctionalBasisforBroad-SpectrumNeutralizationofAvianandHumanInfluenzaAViruses.NatStructMolBio2009,16(3):265-73.CommentedinNatBiotech,NatStructMolBioandNatMed:·WangTT,PaleseP.Universalepitopesofinflenzavirushemagglutinins?NatStructMolBiol(NewsandViews),2009,16(3):233-4.·Chen,GL,SubbaraoK.Attackingtheflu:Neutralizingantibdoiesmayleadto'universal'vaccine.NatMed(BetweenBedsideandBench),2009,15:1251-1252·Influenza'sAchilles'heel?NatBiotech(Researchhighlights),2009,27(14):3483.SuiJ*(*co-correspondingauthor),AirdDR,TaminA,MurakamiA,YanM,Yammanur,A,JingH,KanB,Liu,X,ZhuQ,YuanQ,AdamsGP,BelliniWJ,XuJ,AndersonLJandMarascoWA.BroadeningofNeutralizationActivitytoDirectlyBlockaDominantAntibody-DrivenSARS-CoronavirusEvolutionPathway.PlosPathogen2008,4(11):e10001974.SuiJ.LiW,RobertsA,MatthewsLJ,MurakamiA,VogelL,WongSK,SubbaraoK,FarzanMMarascoWA.Evaluationofhumanmab80rforimmunoprophylaxisofSARSbyananimalstudy,epitopemappingandanalysisofspikevariants.JVirol2005,79(10):5900-59065.SuiJ,LiW,MurakamiA,TaminA,MatthewsLJ,WongSK,MooreMJ,TallricoAS,OlurindeM,ChoeH,AndersonLJ,BelliniWJ,FarzanM,andMarascoWA.PotentNeutralizationofSARSCoronavirusInfectionbyaHumanMonoclonalAntibodyAgainsttheACE2-BindingDomainofSpikeProtein.ProcNatlAcadSciUSA2004,101(8):2536-416.SuiJ,HeY,JiangX,DubelS,HanZ,SongZ.Asinglechainantibodyobtainedbycellpanningofantibodyphageinhibitshomoaggregationofhumanleukemiacells.HumAntibodies2004;13(4):111-1187.SuiJ,BaiJ,TallaricoA,XuCandMarascoWA.IdentificationofCD4andTransferrinReceptorAntibodiesbyAnti-CXCR4AntibodyGuidedPathfinderSelection.EurJBiochem2003;270:4497-45068.SuiJ,MarascoWA.EvidenceagainstEbolavirussGPbindingtohumanneutrophilsbyaspecificreceptor.Virology2002,303(1):9-149.DKChang,SuiJ,GengS,MuvaffakA,BaiM,FuhlbriggeR,LoA,YammanuruA,HubbardL,SheehanJ,CampbellJ,ZhuQ,KupperT,MarascoWA.Humanizationofananti-CCR4antibodythatkillsCutaneousTCellLymphomacellsandabrogatessuppressionbyTregulatorycells.MolecularCancerTherapeutics2012,accepted.10.XuC,SuiJ,TaoH,ZhuQ,WayneA.Marasco.Humananti-CXCR4antibodiesundergoVHreplacement,exhibitfunctionalV-RegionsulfationanddefineCXCR4antigenicheterogeneity.JImmunol2007,179(4):2408-1811.LiW,SuiJ,HuangI-Cheuh,KuhnJH,RadoshizkyS,MarascoWA,ChoeH,FarzanM.TheSproteinsofhumancoronavirusNL63andsevereacuterespiratorysyndromecoronavirusbindoverlappingregionsofACE2.Virology2007,367(2):367-7412.HannahG,SuiJ,FoellmerH,WangT,LedizetM,MurakamiA,NoonanK,LambethC,KarK,AndersonJF,SilvaA,KoskiR,MarascoWA,FikrigE.ProtectionagainstWestNileviruswithhumansinglechainFv-Fcfusionproteinsthatbindtheviralenvelopprotein.JVirol2005,79:14606-461313.BaiJ,SuiJ,DemirjianA,VollmerJrCM,MarascoWA,CalleryMP.PredominantBcl-XLknockdowndisablesantiapoptoticmechanisms:tumornecrosisfactor-relatedapoptosis-inducingligand-basedtriplechemotherapyovercomeschemoresistanceinpancreaticcancercellsinVitro.CancerRes2005,65(6):2344-235214.TarnovitskiN,MatthewsLJ,SuiJ,GershoniJMMarascoWA.MappinganeutralizingepitopeontheSARScoronavirusspikeprotein:computationalpredictionbasedonaffinity-selectedpeptides.JMolBiol2006,359(1):190-20115.LiW,ZhangC,SuiJ,KuhnJH,MooreMJ,LuoS,WongSK,HuangIC,XuK,VasilievaN,MurakamiA,HeY,MarascoWA,GuanY,ChoeH,FarzanM.ReceptorandviraldeterminantsofSARS-coronavirusadaptationtohumanACE2.EMBOJ2005,24:1634-164316.HwangWC,LinY,SantelliE,SuiJ,JaroszewskiL,StecB,FarzanM,MarascoWA,LiddingtonRC.Structuralbasisofneutralizationbyahumananti-SARSSpikeproteinantibody,80R.JBiolChem2006,281(45):34610-617.LiW,MooreMJ,VasilievaN,SuiJ,WongSK,BerneMA,SomasundaranM,SullivanJL,LuzuriagaK,GreenoughTC,ChoeH,FarzanM.Angiotensin-convertingenzyme2isafunctionalreceptorfortheSARScoronavirus.Nature2003,426(6965):450-45418.WrammertJ,KoutsonanosD,LiGM,EdupugantiS,SuiJ,MorrisseyM,McCauslandM,SkountzouI,HornigM,LipkinWI,MehtaA,RazaviB,DelRioC,ZhengNY,LeeJH,HuangM,AliZ,KaurK,AndrewsS,AmaraRR,WangY,DasSR,O'DonnellCD,YewdellJW,SubbaraoK,MarascoWA,MulliganMJ,CompansR,AhmedR,WilsonPC.Broadlycross-reactiveantibodiesdominatethehumanBcellresponseagainst2009pandemicH1N1influenzavirusinfection.JExpMed2011,208(1):181-93特邀综述InvitedReviews1.MarascoWA,SuiJ(*co-correspondingauthor).Thegrowthandpotentialofhumananti-viralmonoclonalantibodytherapeutics.NatureBiotechnology.2007,25(12):1421-34.Invitedreview.专著章节BookChapters1.SuiJ,MarascoWA.ImmunopathogenesisandImmunotherapyofSARS.In:ChanJaneCK,WongVCWTaam.,editor.ChallengesofSevereacuterespiratorysyndrome.HongKong:WBSaunders;2006.p.139-160.专利Patents1.MarascoWA,SuiJ.,AnvirY.HumanizedMonoclonalAntibodiesandMethodsofUse.InternationalApplicationNo.:PCT/US2011/038970.Applicationdate:June03,2011.2.MarascoWA,SuiJ,LiddingtonR.ConservedHemagglutininEpitopes,AntibodiesToTheEpitopeAndMethodsOfUse.PublicationNo.WO/2010/027818.InternationalApplicationNo.:PCT/US2009/054950.Publicationdate:Nov.03,2010.3.MarascoWA,SuiJ,ZhuQ,KupperT.HumanizedMonoclonalAntibodiesandMethodsofUse.PublicationNo.:WO/2009/08651.InternationalApplicationNo.:PCT/US2008/088435.Publicationdate:Sept.07,20094.MarascoWA,SuiJ.AntibodiesagainstH5N1andMethodsofUseThereof.PublicationNo.:WO/2009/079259.InternationalApplicationNo.:PCT/US2008/085876.Publicationdate:June25,2009.5.MarascoWA,SuiJ,XuC.AntibodiesagainstCXCR4andMethodsofUseThereof.PublicationNo.：WO/2006/08941.InternationalApplicationNo.:PCT/US2006/005691.Publicationdate:Aug.24,2006.6.FikrigE,GouldH,KoskiRA,LedizetM,MarascoWA,SuiJ.AntibodiestoWestNileVirusPolypeptides.PublicationNo.：WO/2005/123774.InternationalApplicationNo.:PCT/US2005/022188.Publicationdate:Dec.29,2005.7.MarascoWA,SuiJ.AntibodiesAgainstSARS-CoVandMethodsofUseThereof.U.S.PatentNo.7750，123.Patentexpiration:Nov.23,2024
